Chronic myeloid leukemia: A therapeutic model of molecular biology
Leucemia mieloide crónica: Un modelo terapéutico de biología molecular
Article Sidebar
PDF (Español (España))
FLIP
Main Article Content
Abstract
Chronic myeloid leukemia is a clonal disorder characterized by the proliferation of myeloid elements at all stages of maturation. It was the first neoplasm associated with a constant acquired genetic anomaly and is currently the best studied molecular model of leukemia. The knowledge of the crucial genetic event and the phenotypic abnormalities that it causes, as well as the development of biotechnology, offer a unique opportunity to develop therapies aimed at a molecular target in a rational way. A descriptive, retrospective study was carried out, analyzing the clinical records of the patients treated during the years 1992 to 2002 in the Hematology Service of the Hospital of San José. We analyzed 34 patients with chronic myeloid leukemia; 25 (73.5%) were men. The average age was 43.14 years +/- 14.4. The reason for consultation in the majority of patients (61.8%) was due to general symptoms. Only one was diagnosed during the acceleration phase. A cytogenetic study was performed in 27, of which 20 were Philadelphia positive. The initial treatment was hydroxyurea in 17 patients (50%), busulfan in 5.9%, interferon in 2.9%, hydroxyurea plus busulfan 2.9%. Eight (24%) presented acceleration phase and nine (26%) blast crisis. To date, 25 patients (73.5%) are alive. The median survival was 29.7 months +/- 31.14. Chronic myeloid leukemia is the first successful model of neoplasia treated with substances aimed at the molecular event, and opens the door to new ways of addressing this type of disease.
Downloads
Article Details
References
2. Druker B. Chronic myelogenous leukemia American Society of Hematology 2001: 87-112.
3. O'Brien S, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
4. Okuda K, et al. ARG tyrosine kinase activity is inhibited by ST1571. Blood 2001; 97(8): 2440-2448.
5. Druker B, et al. Activity or a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344 (14):1038-1042.
6. Kantarjian H, et al. Hematologic and citognetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346(9):645-52.
7. Larson R, Wolff S. Chronic myeloid leukemia. En: Wintrobe's Hematology. 10a edición, 2001. Ed. Lippincott Williams y Wilkins. Baltimore, USA, p. 2342-2364.
8. Mauro M, et al. STI571: Targeting BCR-ABL as therapy for CML. The Oncologist 2001; 6:233-38.
9. Druker B, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344 (14):1031-37.
10. Savage D, et al. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346 (9): 683-693.
11. The Italian Cooperative Study Group on chronic myeloid leukemia. Interferon alfa 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-825.
12. Ohniski K, et al. A randomized trial comparing interferon alpha with busulfan for newly diagnosed chronic myeloid leukemia in chronic phase. Blood 1995; 86: 906-916.
13. Hehlmann R, et al. Randomized comparison of interferonalpha with busulfan and hydroxiurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-4077.
14. Guilhot F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337: 223-229.
15. Baccarani M. Interferon alfa for chronic myeloid leukemia. Seminars in Hematology 2003; 40 (1):22-33.
16. Sawyers Ch. Imatinib induces hematologic and citogenetic response in patients with chronic myeloid blast crisis: results of a fase II study. Blood May 2002; 99(10): 3530-3539.
17. Druker B. Chronic myelogenous leukemia. Hematology 2002:111-135.